These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7087040)

  • 21. Calcium and magnesium metabolism during long-term treatment with thiazides.
    Ljunghall S; Backman U; Danielson BG; Fellström B; Johansson G; Wikström B
    Scand J Urol Nephrol; 1981; 15(3):257-62. PubMed ID: 7323748
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterisation of risk factors for stones in hyperuricosuric men attending a stone clinic.
    Walker V; Cook P; Griffin DG
    Urolithiasis; 2014 Aug; 42(4):291-300. PubMed ID: 24894816
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolic effects of bendroflumethiazide in patients with recurrent calcium oxalate stone disease.
    Ahlstrand C; Tiselius HG
    J Urol; 1981 Nov; 126(5):635-9. PubMed ID: 7299925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thiazides in the prophylactic treatment of recurrent idiopathic kidney stones.
    Mortensen JT; Schultz A; Ostergaard AH
    Int Urol Nephrol; 1986; 18(3):265-9. PubMed ID: 3533825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of allopurinol treatment on stone formation on hyperuricosuric calcium oxalate stone-formers.
    Favus MJ; Coe FL
    Scand J Urol Nephrol Suppl; 1980; 53():265-71. PubMed ID: 6938003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum and urinary urate in stone formers.
    Fellström B; Backman U; Danielson BG; Johansson G; Ljunghall S; Wikström B
    Scand J Urol Nephrol Suppl; 1980; 53():187-92. PubMed ID: 6937995
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical characteristics and pathogenetic mechanisms in hyperuricosuric calcium oxalate renal stone disease.
    Favus MJ; Coe FL
    Scand J Urol Nephrol Suppl; 1980; 53():171-7. PubMed ID: 6937993
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Calcium-uric acid nephrolithiasis.
    Coe FL
    Arch Intern Med; 1978 Jul; 138(7):1090-3. PubMed ID: 666467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biochemical effects in patients with calcium oxalate stone disease during combined treatment with bendroflumethiazide and magnesium oxide.
    Ahlstrand C; Tiselius HG
    Br J Urol; 1984 Apr; 56(2):125-30. PubMed ID: 6498431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Physiological and physiochemical correction and prevention of calcium stone formation by potassium citrate therapy.
    Pak CY; Sakhaee K; Fuller CJ
    Trans Assoc Am Physicians; 1983; 96():294-305. PubMed ID: 6679957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Urate nephrolithiasis. Cause of consequence?].
    Mertz DP
    Fortschr Med; 1976 Jul; 94(20-21):1160-4. PubMed ID: 955552
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term treatment of calcium nephrolithiasis with potassium citrate.
    Pak CY; Fuller C; Sakhaee K; Preminger GM; Britton F
    J Urol; 1985 Jul; 134(1):11-9. PubMed ID: 3892044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and biochemical profile of patients with "pure" uric acid nephrolithiasis compared with "pure" calcium oxalate stone formers.
    Negri AL; Spivacow R; Del Valle E; Pinduli I; Marino A; Fradinger E; Zanchetta JR
    Urol Res; 2007 Oct; 35(5):247-51. PubMed ID: 17786420
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Who makes uric acid stones and why--observations from a renal stones clinic.
    Stansbridge EM; Griffin DG; Walker V
    J Clin Pathol; 2013 May; 66(5):426-31. PubMed ID: 23454727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contribution to therapeutic decisions of ratios, absolute values and other measures of calcium, magnesium, urate or oxalate balance in stone formers.
    Drach GW
    J Urol; 1976 Sep; 116(3):338-40. PubMed ID: 957503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of sodium bicarbonate upon urinary citrate excretion in calcium stone formers.
    Pinheiro VB; Baxmann AC; Tiselius HG; Heilberg IP
    Urology; 2013 Jul; 82(1):33-7. PubMed ID: 23602798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biochemical and dietary factors of uric acid stone formation.
    Trinchieri A; Montanari E
    Urolithiasis; 2018 Apr; 46(2):167-172. PubMed ID: 28246885
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biochemical studies in calcium oxalate stone formers, with special reference to the effects of thiazide treatment.
    Ahlstrand C
    Scand J Urol Nephrol Suppl; 1984; 81():1-93. PubMed ID: 6387895
    [No Abstract]   [Full Text] [Related]  

  • 39. [Evaluation of uric acid transport in nephrons of patients with calcium nephrolithiasis and hyperuricosuria].
    Tykarski A; Pupek-Musialik D; Posadzy-Małaczyńska A
    Pol Arch Med Wewn; 1993 Jul; 90(1):26-33. PubMed ID: 8234002
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Calcium stone disease: a multiform reality.
    Trinchieri A; Castelnuovo C; Lizzano R; Zanetti G
    Urol Res; 2005 Jun; 33(3):194-8. PubMed ID: 15714335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.